Medtech deal value rose year over year and rebounded above pre-2023 levels, bolstered by renewed strategic confidence and several large transactions. The second half of the year was particularly strong, nearly doubling first-half deal value as valuations continued to decline. Robust dealmaking is likely to continue into 2026. One standout trend was the rise in spin-offs and divestitures, which accounted for more than a third of strategic deal value in the first 11 months of 2025—a noticeable increase from the previous five-year average. In 2026, the possibility of even softer valuations will intensify competition for quality assets, making speed, conviction, and disciplined execution essential to success.
Read the full article: Bain: M&A in Medtech – The Boom in Portfolio Reshaping //
Source: https://www.bain.com/insights/medtech-m-and-a-report-2026/